It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Predicting drug-induced liver injury in a preclinical setting remains challenging, as cultured primary human hepatocytes (PHHs), pluripotent stem cell-derived hepatocyte-like cells (HLCs), and hepatoma cells exhibit poor drug biotransformation capacity. We here demonstrate that hepatic functionality depends more on cellular metabolism and extracellular nutrients than on developmental regulators. Specifically, we demonstrate that increasing extracellular amino acids beyond the nutritional need of HLCs and HepG2 cells induces glucose independence, mitochondrial function, and the acquisition of a transcriptional profile that is closer to PHHs. Moreover, we show that these high levels of amino acids are sufficient to drive HLC and HepG2 drug biotransformation and liver-toxin sensitivity to levels similar to those in PHHs. In conclusion, we provide data indicating that extracellular nutrient levels represent a major determinant of cellular maturity and can be utilized to guide stem cell differentiation to the hepatic lineage.
Hepatocytes grown in a dish are immature and do not metabolize compounds as a real liver would. Here, the authors supply stem cell-derived hepatocytes with amino acids at a higher concentration than nutritionally necessary, changing the metabolism of these cells, making them more mature and useful for drug screening and toxicity studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Kumar, Manoj 1
; Tricot Tine 1 ; Elia Ilaria 2 ; Ordovas, Laura 3
; Jacobs, Frank 4 ; One, Jennifer 5 ; De Smedt Jonathan 1 ; Eelen Guy 6
; Bird, Matthew 7 ; Roelandt, Philip 8
; Doglioni Ginevra 2 ; Vriens, Kim 2 ; Rossi, Matteo 2 ; Vazquez, Marta Aguirre 1 ; Vanwelden, Thomas 1 ; Chesnais François 1
; Adil, El Taghdouini 9 ; Najimi Mustapha 9
; Sokal Etienne 9 ; Cassiman, David 7
; Snoeys, Jan 5
; Monshouwer Mario 5 ; Wei-Shou, Hu 5 ; Lange, Christian 6 ; Carmeliet, Peter 6
; Sarah-Maria, Fendt 2
; Verfaillie, Catherine M 1
1 Stem Cell Institute, KU Leuven, Department of Development and Regeneration, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
2 VIB Center for Cancer Biology, VIB, Laboratory of Cellular Metabolism and Metabolic Regulation, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); KU Leuven and Leuven Cancer Institute (LKI), Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
3 Stem Cell Institute, KU Leuven, Department of Development and Regeneration, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); IIS Aragón University of Zaragoza, Aragon I + D Foundation (ARAID), Biomedical Signal Interpretation and Computational Simulation (BSICoS) Group, Aragón Institute of Engineering Research, Zaragoza, Spain (GRID:grid.488737.7) (ISNI:0000000463436020)
4 Janssen Research and Development, Beerse, Belgium (GRID:grid.419619.2) (ISNI:0000 0004 0623 0341)
5 University of Minnesota, Department of Chemical Engineering and Materials Science, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657); University of Minnesota, Stem Cell Institute, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
6 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center of Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040)
7 KU Leuven, Hepatology, Department of Clinical and Experimental Medicine, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
8 Stem Cell Institute, KU Leuven, Department of Development and Regeneration, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); KU Leuven, Hepatology, Department of Clinical and Experimental Medicine, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); KU Leuven, Translational Research in GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)
9 Universit Catholique de Louvain & Cliniques Universitaires St Luc, Institut de Recherche Clinique et Expérimentale (IREC), Laboratory of Pediatric Hepatology and Cell Therapy, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)




